July 10, 2026

Written by Dr. Vincent Angelico

A premarket tobacco product application, or PMTA, is the application a company files to get FDA permission to sell a nicotine product. One question comes up on nearly every nicotine pouch program: Does the application need a direct switching study, meaning a study that measures whether adult smokers actually move over to the new product? The short answer is that the FDA does not require one in every case. Whether you need one depends on how strong the rest of your evidence is.

Under Section 910 of the Federal Food, Drug, and Cosmetic Act and its rule at 21 CFR Part 1114, the FDA can authorize a product only if marketing it is appropriate for the protection of the public health. That phrase is often shortened to APPH. The FDA makes this judgment for the whole population, both people who already use tobacco and people who do not. So the agency weighs the benefits to adults who might switch to a lower-risk product against the risk that nonusers, especially young people, might start using it.

The application has to address how people’s behavior is likely to change. That means switching, quitting, starting, and using more than one product at the same time. These questions sit at the center of the analysis.

The rule requires you to address these behavior outcomes, but it does not require every application to include a direct switching study to do so. Part 1114 lists the information an application must contain and the standard FDA must apply. It does not name a required clinical switching trial. You can build the behavior case from several kinds of evidence, and the FDA judges the application on the strength of the whole record.

Two authorizations show how the FDA has accepted the behavior and benefit evidence for nicotine pouches. ZYN leaned on direct switching data. on! PLUS leaned on a broader evidence package.

ZYN (Swedish Match / Philip Morris)

When the FDA authorized ZYN pouches, it pointed to the company’s evidence that a large share of adults who smoke cigarettes or use other smokeless tobacco switched completely to the authorized products. FDA’s science leadership described the decision as supported by evidence that adults who switch completely can benefit, and concluded that this adult benefit outweighed the product’s risks, including risks to young people. Proven complete switching among adults is a strong, convincing support.

on! PLUS (Helix Innovations / Altria)

When the FDA authorized six on! PLUS products reached their decision by weighing the full set of evidence rather than relying on any single required study. The evidence that the FDA credited included:

• Product chemistry showing lower levels of harmful and potentially harmful constituents (HPHCs, the toxic chemicals measured in tobacco products) than cigarettes and other smokeless tobacco, with several cancer-causing chemicals not present at measurable levels;
• Abuse-liability and pharmacokinetic (PK) data, that is, how the body absorbs nicotine, and how satisfying users found the product, from a clinical study in adults who used smokeless tobacco;
• Published and category-level research on how people switch to nicotine pouches;
• Bridging from the tested products to the rest of the product family, based on similar total and free nicotine;
• Marketing limits, youth-access and youth-risk controls, and postmarket requirements.

The FDA’s review noted that for low-risk products like pouches, the amount of adult-benefit evidence needed is lower than for higher-risk products, because pouches pose a relatively low risk compared to cigarettes and other smokeless tobacco. The FDA used PK and subjective-effect data to determine whether the products could serve as acceptable substitutes for higher-risk products, and it relied on existing switching research rather than requiring a product-specific switching trial.

What the precedent tells us. The FDA has authorized nicotine pouches on the strength of chemistry and HPHC data, PK and abuse-liability data, bridging, research, and strong youth controls. The behavior and benefit case can be carried by a mix of evidence. A direct switching study has not worked as a required gate.

The youth-use picture

The most recent youth survey data sets the risk side of the balance and shows how much weight your youth will have to carry. The figures below come from the National Youth Tobacco Survey (NYTS), an annual federal survey of middle and high school students, with 2025 data published in June 2026.

How to think about the study decision

A switching study is not required. Neither Section 910 nor Part 1114 calls for one, and the ZYN and on! PLUS decisions confirm the behavior and benefit case can be met through the full evidence package.

It’s often worth doing anyway. A well-designed switching study gives some of the most direct evidence available that adults who smoke or use other smokeless tobacco will switch completely or cut back substantially.

When a no-study path can work

A direct switching study is not categorically required, but its added value should be weighed against the uncertainty that remains in your APPH case. Whether you need one depends on your specific product. It comes down to whether your evidence package clears the same benefit-risk bar covered above.

Where the package is strong, with product-specific PK and abuse-liability data, chemistry and HPHC reduction data, supportive research, sound bridging, consumer-perception and use-intention evidence, and strong youth controls, the FDA precedent suggests an application can hold up without a switching study. Where those data are weak, uncertain, or hard to bridge to the product at hand, a switching study can become important, even close to necessary, because it answers the behavior question that the other evidence leaves open.

The two realistic paths, side by side:

What this means for applicants

• If budget and timing allow, run or include a well-designed switching study. A direct study clearly strengthens the adult-benefit case and answers the behavior question at the center of the analysis, which lowers review risk and the chance of a deficiency request from the FDA.
• If timing does not allow, build a solid rationale for going without one. Ground it in product-specific PK and abuse-liability data, HPHC reduction, supportive research, bridging, and consumer use-intention and perception evidence. That tracks the evidence the FDA cited in! PLUS.
• Frame the position with care. Do not tell the FDA that the study is simply not needed. Say instead that a switching study is not categorically required, explain why your overall package is strong enough without one, and document that judgment in the application.

How Accorto can help

We work through the switching-study question first, then build the strongest defensible submission on the path you choose. A typical engagement runs in four phases. 

Phase 1: Evidence gap review (about 2 to 4 weeks) 

• Take stock of the data you already have: product chemistry and HPHC, PK and abuse-liability, stability, consumer perception, and any earlier behavior data. 
• Match each evidence element against what FDA precedent expects, and grade the APPH uncertainty that remains. 
• Deliver a clear recommendation on whether to run a switching study, with a rationale FDA can follow. 

Phase 2: Study design or no-study rationale 

• If a study makes sense, design a well-powered switching or actual-use study, covering endpoints, comparator, length, and use-behavior measures, aligned with what the FDA looks for. 
• If it does not, draft a solid rationale built on PK and abuse-liability, HPHC reduction, research, bridging, and use-intention evidence, framed as not categorically required, with the added value weighed against the uncertainty that remains. 

Phase 3: Youth-risk controls and population-health module 

• Build the labeling, marketing limits, age checks, access controls, child-resistant packaging, and postmarket tracking package. 
• Set your product against the current NYTS data so the risk and benefit balance is laid out on FDA’s own terms. 

Phase 4: Application assembly and filing 

• Pull together the full Part 1114 application, including product bridging, scientific summaries, and the combined APPH argument. 
• Run a pre-submission quality and deficiency-risk review, then support you through FDA review correspondence. 

A Phase 1 evidence gap review provides a documented, precedent-based recommendation on whether your pouch line needs a switching study, along with a roadmap and budget for the full submission, usually within 4 weeks. 

Dr. Vincent Angelico

Chief Science Officer & Co-Founder

Dr. Vincent Angelico is the Chief Science Officer and a co-founder of Accorto Regulatory Solutions. He holds a PhD in Analytical Chemistry and specializes in FDA regulatory strategy for tobacco harm reduction products, with deep experience in PMTA submissions, consumer behavior research, and population-health analysis for nicotine pouches and smoke-free alternatives. He has guided THR programs through every stage of the FDA review process, from initial product classification through substantive review and deficiency response.

This is general regulatory and scientific analysis from Accorto Regulatory Solution. It reflects FDA decisions and public information available as of June 2026 and is not legal advice. Regulatory expectations change, so please confirm current FDA guidance and authorized-product details before acting on anything here.